인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
피인용 0
초록·키워드
Purpose: The biallelic expression of insulin-like growth
factor-II (IGF2) and H19 has been reported to be associated
with the progression of several tumors. Here,
the promoter usage and expression levels of IGF2 and
H19 are reported to be altered in cervical and endometrial
cancers showing loss of imprinting (LOI).
Materials and Methods: The imprinting status of IGF2
and H19 was examined in 32 cervical carcinomas, their
matched normal tissues, 13 endometrial cancer and 33
normal endometrial tissues.
Results: The LOI of IGF2 was observed in 7 of 18 (39%)
and 1 of 13 (8.3%) informative cervical carcinomas and
informative endometrial cancers, respectively. The LOI of
the H19 gene was detected in 5 of 14 (36%) and in all
11 (100%) informative cervical carcinoma cases and
informative endometrial cancer cases, respectively. The
use of promoter P1 was observed in the LOI tumors
of IGF2, but not in the tumors showing maintenance of
IGF2 imprinting (MOI), or in cervical and endometrial
cancers. Unlike MOI tumors, some LOI tumors revealed
a lack of IGF2 transcription from the promoter P3. The
LOI tumors of IGF2 showed increased expression of the
IGF2 level, but a down-regulation of the H19, relative to
normal tissues, whereas the MOI tumors revealed no
significant alterations.
Conclusion: These results suggest that the promoter P1
could be involved in the biallelic expression of IGF2, and
that the altered expression of the IGF2 and H19 levels
might be associated with the progression of cervical and
endometrial cancers that exhibit biallelic IGF2 expression.
(Cancer Res Treat. 2003;35:314-322)
본문·목차
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
